Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Immunomedics Shares Are Skyrocketing Today

By Todd Campbell - Apr 23, 2020 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company won an early FDA approval yesterday for its drug to treat advanced breast cancer.

What happened

After the Food and Drug Administration approved the company's advanced breast cancer drug Trodelvy on Wednesday, the stock of Immunomedics (IMMU) surged 22.9% as of 11:25 a.m. EDT on Thursday.

So what

The FDA was expected to issue its go/no-go decision for Trodelvy on June 2. Instead, it gave the drug an early go-ahead, ostensibly because of the significant need for treatment options in heavily pre-treated metastatic triple-negative breast cancer (mTNBC).

Rubber stamp with FDA and pills on craft paper. -

Image source: Getty Images.

Trodelvy's path to the FDA's finish line was undeniably bumpy. Efforts to win approval in 2019 were scuttled when manufacturing concerns caused the FDA to issue a complete response letter rather than a regulatory green light. A management shake-up followed, and the healthcare company wasn't able to refile Trodelvy for approval until December, after it replaced its contract manufacturer. 

The FDA's blessing clears the way for Immunomedics to begin marketing Trodelvy's advantages as a third-line treatment option. In trials, the anti-TROP-2 antibody drug conjugate delivered an overall response rate of 31%, outperforming the mid-teen response rates historically witnessed within this patient population. 

Now what

Every year, there are about 246,660 newly diagnosed breast cancer cases, and roughly 15% of them are TNBC. Because TNBC can advance quickly and many patients develop resistance to chemotherapy, Trodelvy could win widespread use in the third-line treatment setting.

However, the jump to commercialization can be difficult. Since Immunomedics shares have already rallied sharply this year, investors may want to be cautious until data for Trodelvy as an early therapy is available, or there's insight into how quickly sales are ramping up in late-line patients. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
IMMU

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.